News | Heart Valve Technology | August 22, 2019

Edwards Recalls Sapien 3 Ultra Delivery System Due to Burst Balloons During Surgery

FDA says burst balloons may result in vascular injury, bleeding or surgical intervention

Edwards Recalls Sapien 3 Ultra Delivery System Due to Burst Balloons During Surgery

August 22, 2019 — Edwards Lifesciences is recalling the Sapien 3 Ultra delivery system after receiving reports of burst balloons during implantation procedures, which have resulted in significant difficulty retrieving the valve into the catheter and withdrawing the system from the patient. The company said this may cause vascular injury, bleeding or surgical intervention.

Seventeen injuries and one death were reported at the time when Edwards initiated the Field Corrective Action in July 2019.

The Edwards Sapien 3 Ultra delivery system is a part of the Edwards Sapien 3 transcatheter heart valve system. It is used to deliver and deploy the Edwards Sapien 3 Ultra or the Edwards Sapien 3 transcatheter heart valve to replace a diseased aortic valve without open-heart surgery. The Sapien 3 is indicated for use in patients with severe, symptomatic, aortic valve stenosis, a narrowing of the heart’s aortic valve that restricts blood flow to aorta, the body’s main artery.

The recall affects all lot numbers manufactured between Jan. 23, 2018 and July 16, 2019; the devices would have been involved in procedures starting Jan. 3 of this year. A total of 1,585 devices in the U.S. are affected by the recall. 

In the Urgent Field Safety Notice to customers, Edwards provided the following recommendations and instructions for physicians:

  1. When deploying the valve, inflate the balloon slowly and continuously throughout deployment. Hold for 3 seconds at full inflation. The delivery system requires a prescribed volume for THV deployment and proper function (11 mL, 17 mL, 23 mL, 33 mL).

  2. The following warning will also be added to the Edwards Sapien 3 Ultra Transcatheter Heart Valve System Instructions for Use (IFU): "Failure to use slow, controlled inflation and prescribed nominal inflation volumes may result in balloon rupture, difficulty retrieving the delivery system and may require subsequent conversion to surgical intervention."

  3. If a balloon burst is suspected, do not attempt to pull back the delivery system into the sheath until you are prepared to conduct the following technique:

    1. Close stopcock to the delivery system and remove inflation device from stopcock.

    2. Continuously twist the handle in a clockwise direction (full 360° rotations) while gently pulling back the delivery system into the sheath tip. Verify delivery system tip has entered the sheath tip under fluoroscopy.

    3. Do not force if resistance is met near or at the sheath tip. Forcing retrieval when meeting resistance could result in additional balloon material tearing or tip dislodgement. Consider utilizing other interventional techniques for retrieval (e.g., a snare).

    4. If successful in pulling the entire balloon into the tip of the sheath, withdraw the delivery system and sheath as a single unit completely from the arteriotomy while maintaining guidewire position. Do not attempt to pull the delivery system through the remaining length of the sheath.

    5. If resistance is still encountered, convert to surgery for device removal. Based on medical assessment of the size, tortuosity and extent of calcification of the peripheral vessels, evaluate the risks and tradeoffs of carefully withdrawing the system into a more peripheral anatomy in order to allow a more localized procedure. Consider use of an occlusion balloon to mitigate bleeding risks.

Edwards also asked physicians to review the acknowledgment form, sign and date it, and return it to their Edwards representative or fax/email it as instructed on the form attached.

Healthcare professionals and consumers may report adverse reactions or quality problems they experience using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program either online, by regular mail or by Fax to 1-800-FDA-0178.

For more information: www.edwards.com


Related Content

News | Cath Lab

December 20, 2023 — Jason R. McCarthy, Ph.D., associate professor of biomedical research and translational medicine and ...

Home December 20, 2023
Home
News | Cath Lab

October 26, 2023 — Royal Philips, a global leader in health technology, announced the latest results demonstrating the ...

Home October 26, 2023
Home
News | Cath Lab

October 25, 2023 — Shockwave Medical, Inc., a pioneer in the development and commercialization of transformational ...

Home October 25, 2023
Home
News | Cath Lab

October 20, 2023 — Over the coming days, Philips will be presenting its latest solutions in cardiology and new late ...

Home October 20, 2023
Home
News | Cath Lab

October 16, 2023 — GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest ...

Home October 16, 2023
Home
News | Cath Lab

October 16, 2023 — Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, announced the first U.S ...

Home October 16, 2023
Home
News | Cath Lab

September 13, 2023 — A diagnostic test, first offered in the United States at University Hospitals (UH) Harrington Heart ...

Home September 13, 2023
Home
News | Cath Lab

August 2, 2023 — Teleflex Incorporated, a leading global provider of medical technologies, announced the U.S Food and ...

Home August 02, 2023
Home
News | Cath Lab

July 13, 2023 — Mount Sinai Queens announced the opening of a new cardiac catheterization lab that will provide rapid ...

Home July 13, 2023
Home
News | Cath Lab

June 21, 2023 — Royal Philips, a global leader in health technology, announced it has teamed up with BIOTRONIK (Lake ...

Home June 21, 2023
Home
Subscribe Now